Effects of intracoronary melatonin on ischemia–reperfusion injury in ST-elevation myocardial infarction
- 467 Downloads
Acute coronary occlusion is effectively treated by primary percutaneous coronary intervention. However, myocardial ischemia–reperfusion injury is at the moment an unavoidable consequence of the procedure. Oxidative stress is central in the development of ischemia–reperfusion injury. Melatonin, an endogenous hormone, acts through antioxidant mechanisms and could potentially minimize the myocardial injury. The aim of the experimental study was to examine the cardioprotective effects of melatonin in a porcine closed-chest reperfused infarction model. A total of 20 landrace pigs were randomized to a dosage of 200 mg (0.4 mg/mL) melatonin or placebo (saline). The intervention was administered intracoronary and intravenous. Infarct size, area at risk and microvascular obstruction were determined ex vivo by cardiovascular magnetic resonance imaging. Myocardial salvage index was calculated. The plasma levels of high-sensitive troponin T were assessed repeatedly. The experimenters were blinded with regard to treatment regimen. Melatonin did not significantly increase myocardial salvage index compared with placebo [melatonin 21.8 % (16.1; 24.8) vs. placebo 20.2 % (16.9; 27.0), p = 1.00]. The extent of microvascular obstruction was similar between the groups [melatonin 3.8 % (2.7; 7.1) vs. placebo 3.7 % (1.3; 7.7), p = 0.96]. The area under the curve for high-sensitive troponin T release was insignificantly reduced by 32 % in the melatonin group [AUC melatonin 12,343.9 (6,889.2; 20,147.4) ng h/L vs. AUC placebo 18,285.3 (5,180.4; 23,716.8) ng h/L, p = 0.82]. Combined intracoronary and intravenous treatment with melatonin did not reduce myocardial reperfusion injury. The lack of a positive effect could be due to an ineffective dose of melatonin, a type II error or the timing of administration.
KeywordsAcute myocardial infarction Reperfusion injury Animal experimentation Oxidative stress Antioxidant
A special thanks to the Department of Diagnostic Imaging, the Laboratory of Biomedical Science and the staff at the Department of Cardiology, Aalborg University Hospital, Denmark. This work was supported by grants from the Lundbeck Foundation, the Aase and Ejnar Danielsens Foundation, the A. P. Møller Foundation for the Advancement of Medical Science, the Axel Muusfeldts Foundation, the Arvid Nilssons Foundation and the Snedkermester Sophus Jacobsens Foundation. These funders have had no influence on the study design, data collection, analysis and interpretation of data, or writing of the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.(1997) A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The global use of strategies to open occluded coronary arteries in acute coronary syndromes (GUSTO IIb). Angioplasty Substudy Investigators. N Engl J Med 336:1621–1628Google Scholar
- 7.Guan W, Osanai T, Kamada T, Hanada H, Ishizaka H, Onodera H, Iwasa A, Fujita N, Kudo S, Ohkubo T, Okumura K (2003) Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol 41:699–705PubMedCrossRefGoogle Scholar
- 22.Gitto E, Tan DX, Reiter RJ, Karbownik M, Manchester LC, Cuzzocrea S, Fulia F, Barberi I (2001) Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J Pharm Pharmacol 53:1393–1401PubMedCrossRefGoogle Scholar
- 24.Petrosillo G, Colantuono G, Moro N, Ruggiero FM, Tiravanti E, Di Venosa N, Fiore T, Paradies G (2009) Melatonin protects against heart ischemia–reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Am J Physiol Heart Circ Physiol 297:H1487–H1493PubMedCrossRefGoogle Scholar
- 31.Gögenur I, Kücükakin B, Panduro Jensen L, Reiter RJ, Rosenberg J (2014) Melatonin reduces cardiac morbidity and markers of myocardial ischemia after elective abdominal aortic aneurism repair: a randomized, placebo-controlled, clinical trial. J Pineal Res. doi: 10.1111/jpi.12138
- 33.Van der Pals J, Koul S, Andersson P, Götberg M, Ubachs JF, Kanski M, Arheden H, Olivecrona GK, Larsson B, Erlinge D (2010) Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia–reperfusion model. BMC Cardiovasc Disord 10:45PubMedPubMedCentralCrossRefGoogle Scholar
- 34.Ubachs JF, Engblom H, Koul S, Kanski M, Andersson P, van der Pals J, Carlsson M, Erlinge D, Arheden H (2013) Myocardium at risk can be determined by ex vivo T2-weighted magnetic resonance imaging even in the presence of gadolinium: comparison to myocardial perfusion single photon emission computed tomography. Eur Heart J Cardiovasc Imaging 14:261–268PubMedCrossRefGoogle Scholar
- 39.Pérez de Prado A, Cuellas-Ramón C, Regueiro-Purriños M, Gonzalo-Orden JM, Pérez-Martínez C, Altónaga JR, García-Iglesias MJ, Orden-Recio MA, García Marín JF, Fernández-Vázquez F (2009) Closed-chest experimental porcine model of acute myocardial infarction–reperfusion. J Pharmacol Toxicol Methods 60:301–306PubMedCrossRefGoogle Scholar
- 43.Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Gutberlet M, Schuler G (2010) Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) trial. J Am Coll Cardiol 55:2201–2209PubMedCrossRefGoogle Scholar
- 45.Lønborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, Jørgensen E, Helqvist S, Saunamäki K, Terkelsen CJ, Schoos MM, Køber L, Clemmensen P, Treiman M, Engstrøm T (2012) Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 5:288–295PubMedCrossRefGoogle Scholar
- 46.Maruhashi T, Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nakama Y, Kagawa E, Dai K, Matsushita J, Ikenaga H (2010) Effect of prodromal angina pectoris on the infarct progression in patients with first ST-elevation acute myocardial infarction. Circ J 74:1651–1657PubMedCrossRefGoogle Scholar
- 47.Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC, Reiter RJ, Jimenez-Sosa A (2007) A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: study design and rationale. Contemp Clin Trials 28:532–539PubMedCrossRefGoogle Scholar